Big Pharma Approvals β April 03, 2026
This period features 4 Other approvals (0 NME, 0 biosimilar, 0 label expansion), with a focus on rare disease assets underscored by Orphan Drug designations. Vertex Pharmaceuticals dominates with two Priority Review supplemental NDA approvals for TRIKAFTA (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR), signaling label enhancements in cystic fibrosis and reinforcing franchise strength. Highest-conviction signal is Eli Lilly and Co's NME approval for Unknown under Priority Review, a bullish execution milestone with potential 5-year exclusivity despite undisclosed commercial details. Biogen Inc's Nusinersen Sodium approval is neutral with limited data. Key risk/watch item: Uncertain label details and post-approval uptake for Vertex supplements; full commercial profile for Lilly's Unknown remains NOT_DISCLOSED.